Aligos Theraptcs Rg
Clinical‑stage biopharma focused on viral & liver disease therapeutics, with Phase 2a NASH candidate ALG‑055009, Phase 1b CHB capsid modulator ALG‑000184, and siRNA CHB candidate ALG‑125755. Strategic collaborations with Merck, Luxna, Emory, and academic partners.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 70
- HQ: South San Francisco
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.